Am J Transplant, Volume 20, Suppl 3 Archives - Page 151 of 223 - ATC Abstracts

2020 American Transplant Congress
Medication Knowledge Retention and Adherence Following Transplant: Is There Room for Improvement?
M. H. Cooper¹, A. W. Rogers¹, T. L. Menser², J. C. Krisl¹
¹Department of Pharmacy, Houston Methodist Hospital, Houston, TX, ²Houston Methodist Research Institute, Houston Methodist Hospital, Houston, TX
*Purpose: Transplant recipients’ complex medication regimens following transplant can lead to non-adherence, which has been linked to increased rates of acute rejection and graft loss.…
2020 American Transplant Congress
Impact of Alemtuzumab Induction on Cardiac Allograft Vasculopathy in Orthotopic Heart Transplant Recipients
M. Plazak¹, X. Gao², S. Gale², B. Reed², R. Madathil¹, S. Hammad¹, B. Ravichandran¹
¹University of Maryland Medical Center, Baltimore, MD, ²University of Maryland School of Pharmacy, Baltimore, MD
*Purpose: Cardiac allograft vasculopathy (CAV) is impacted by acute rejection and ultimately limits long-term survival of orthotopic heart transplant (OHT) recipients, thus there is interest…
2020 American Transplant Congress
Combined Heart-Liver Transplantation Has Excellent Long-Term Outcomes
J. A. Steadman¹, J. M. Stulak¹, A. L. Clavell², S. S. Kushwaha², B. S. Edwards², N. L. Pereira², B. A. Boilson², A. Behfar², R. J. Rodeheffer², J. A. Dearani¹, T. Taner³, R. C. Daly¹
¹Division of Cardiovascular Surgery, Mayo Clinic, Rochester, MN, ²Division of Cardiovascular Disease, Mayo Clinic, Rochester, MN, ³Division of Transplantation Surgery, Mayo Clinic, Rochester, MN
*Purpose: Combined heart-liver transplants (CHLTx) have been shown to have good short-term outcomes in those with end-stage heart and liver disease: we conducted a comprehensive…
2020 American Transplant Congress
Transpulmonary Gradient as a Predictor for Outcomes after Single Lung Transplantation in Patients with Pulmonary Hypertension
A. Madde¹, E. Chan², J. Ryan², P. Reck Dos Santos², M. Morrell³, J. Luketich², P. Sanchez²
¹University of Pittsburgh School of Medicine, Pittsburgh, PA, ²UPMC Department of Cardiothoracic Surgery, Pittsburgh, PA, ³UPMC Division of Pulmonary Medicine, Pittsburgh, PA
*Purpose: End stage lung disease is commonly associated with pulmonary artery hypertension (PAH). In a donor restrictive environment, offering patients single over double lung transplants…
2020 American Transplant Congress
Oral versus Intravenous Mycophenolate Mofetil Administration: A Single Center Experience on Incidence of Acute Kidney Injury
P. Chung¹, K. Forrester², S. Ganesh¹
¹Division of Pulmonary Critical and Sleep Medicine, University of Southern California, Los Angeles, CA, ²Department of Clinical Pharmacy, University of Southern California School of Pharmacy, Los Angeles, CA
*Purpose: Mycophenolate mofetil (MMF) is one of the main immunosuppressive medications given in lung transplantation (LTx). It is given orally (PO) or intravenously (IV). In…
2020 American Transplant Congress
A Novel Formula to Determine Optimal Immunosuppression in Renal Transplant Recipients Treated with Tacrolimus and Mycophenolate Mofetil: Towards Individualized Immunosuppression
O. Pankewycz¹, M. Laftavi¹, E. Onan², D. Rucker¹, D. Wang¹, K. Bhuta¹, R. Gruessner³, A. Gruessner³
¹SUNY, Upstate Medical University, Syracuse, NY, ²Cukurova University, Adana, Turkey, ³SUNY, Downstate Medical University, New York, NY
*Purpose: Tacrolimus (TAC) and mycophenolic acid (MPA) remain the most commonly used drug combination for kidney transplant immunosuppression. Adequate drug dosing is challenging due to…
2020 American Transplant Congress
An Immune-Modulatory Strategy to Mitigate Hepatic Ischemia Reperfusion/Injury in a Murine Model
A. Kobayashi¹, A. Wanchoo², J. Simonovich², S. Duarte¹, V. Boominathan¹, S. Shrestha¹, G. Hudalla², B. Keselowsky²
¹Surgery, University of Florida, Gainesville, FL, ²Biomedical Engineering, University of Florida, Gainesville, FL
*Purpose: Hepatic ischemia/reperfusion injury (IRI) is the leading cause of early graft dysfunction and contributes to the shortage of donor organs. However, despite its obvious…
2020 American Transplant Congress
The Pleural Cavity, A Novel and Clinically Relevant Site for Pancreatic Islet Transplantation
Q. Yuan¹, K. Lee¹, C. Rickert¹, S. Hong¹, E. Acheampong¹, E. Szuter¹, Y. Xu², K. Deng¹, N. Feeney¹, Q. Fu¹, G. Huai¹, J. Lei¹, I. Rosales¹, P. Russell¹, J. Madsen¹, R. Colvin¹, A. Alessandrini¹, J. Markmann¹, -. Q.Y. and K.L.³, -. A.A. and J.F.M.⁴
¹Massachusetts General Hospital, Boston, MA, ²Chinese PLA General Hospital & Medical School, Beijing, China, ³Co-First Authors, Boston, MA, ⁴Co-Senior Authors, Boston, MA
*Purpose: Islet transplantation currently provides a cure for type 1 diabetes. Hepatic infusion of islets via the portal vein is clinically accepted in human, although…
2020 American Transplant Congress
Unique Podocyte and Multiplex Single-Cell RNASeq Analysis of Paired Sera and Bone Marrow Samples Suggest a Role for Perturbed Hematopoeitic Progenitors in FSGS Recurrence
P. Rashmi, T. Sigdel, A. Alica Da Silva, R. Paul, D. Galligan, J. Wolfe, F. Vincenti, M. Sarwal
University of California San Francisco, San Francisco, CA
*Purpose: Focal Segmental Glomerulosclerosis (FSGS) is the most common cause of nephrotic syndrome, can lead to ESRD, and carries a high burden of recurrence risk…
2020 American Transplant Congress
Prevalence of Risk Factors for NAFLD among Living Liver Donors
D. A. Axelrod¹, M. Simpson², E. Pomfret³, A. Ehrlich⁴, S. Rwema⁴, R. Chung⁴, F. Gordon⁵
¹Surgery, University of Iowa, Iowa CIty, IA, ²Surgery, Lahey Clinic, Burlington, MA, ³University of Colorado, Denver, CA, ⁴Mass General Hospital, Boston, MA, ⁵Lahey, Burlington, MA
*Purpose: The development of non-alcoholic fatty liver (NAFLD) disease has been strongly associated with the presence of polymorphisms in PNPLA3 rs738409. When compared with wild…